ADC Pipeline in South Korea

South Korea has rapidly emerged as a hub for next-generation cancer therapeutics, with a growing number of biopharmaceutical companies advancing antibody-drug conjugate (ADC) technologies. Combining strong research infrastructure, government support, and deep expertise in biologics, Korean innovators are developing highly targeted ADCs that aim to improve efficacy while minimizing toxicity—reshaping the future of care.

Download the e-Book HERE
‍

Complete the Form to Access the Webinar Video

First Name

Last Name

Professional E-mail

Job Title

Company Name

Phone Number

Country

You acknowledge and agree to IMAPAC's Term of Service and to use your contact information provided to communicate with about offerings by IMAPAC, its brands, affiliates and/or third-party partners consistent with IMAPAC's Privacy Policy.

Thank you! Click below to view/download:

Oops! Something went wrong while submitting the form.